{"id":{"repo_id":"bu","oai_identifier":"oai:open.bu.edu:2144/53644"},"canonical_url":"https://search.ndltd.org/etd/bu/oai:open.bu.edu:2144/53644","repository":{"repo_id":"bu","name":"Boston University","base_url":"https://open.bu.edu/oai/request"},"display":{"title":"Development of a CRISPR-Cas9 paired-guide RNA deletion strategy for functional studies of sex-biased genes in mouse liver","abstract":"In mice, as well as rats and humans, pituitary growth hormone (GH) secretion patterns exhibit distinct sexual dimorphism. This sex differential secretion pattern drives sex-biased expression of numerous long non-coding RNAs (lncRNAs) and protein-coding genes (PCGs). The regulation and functional roles of these genes within the GH gene regulatory network are understudied, but have been associated with liver disease, including non-alcoholic fatty liver disease (NAFLD). To address this gap, we developed a CRISPR-Cas9-mediated paired-guide RNA (pgRNA) deletion strategy as a loss-of-function model to generate targeted genomic deletions within identified sex-biased genes. The original design was established in NIH3T3 cells by co-transfection of pgRNA and CRISPR-Cas9 plasmids targeting deletions in lncRNAs and expanded to a lentiviral co-infection system targeting both lncRNAs and PCGs, generating double-strand breaks that produced targeted deletions within the selected loci. We next adapted this design for in vivo AAV8 co-delivery to mouse liver, where we observed low-frequency genomic deletions at the targeted loci, highlighting the need for further optimization of in vivo editing conditions. Collectively, the application of the pgRNA deletion strategy across three distinct delivery platforms —plasmid transfection, lentiviral infection, and AAV8 injection—with variable degrees of success demonstrates the versatility and adaptability of the knockout model for targeting multiple genes within the GH regulatory network and establishes a flexible framework for investigating additional gene networks with potential disease relevance, including pathways linked to NAFLD.","abstract_html":"In mice, as well as rats and humans, pituitary growth hormone (GH) secretion patterns exhibit distinct sexual dimorphism. This sex differential secretion pattern drives sex-biased expression of numerous long non-coding RNAs (lncRNAs) and protein-coding genes (PCGs). The regulation and functional roles of these genes within the GH gene regulatory network are understudied, but have been associated with liver disease, including non-alcoholic fatty liver disease (NAFLD). To address this gap, we developed a CRISPR-Cas9-mediated paired-guide RNA (pgRNA) deletion strategy as a loss-of-function model to generate targeted genomic deletions within identified sex-biased genes. The original design was established in NIH3T3 cells by co-transfection of pgRNA and CRISPR-Cas9 plasmids targeting deletions in lncRNAs and expanded to a lentiviral co-infection system targeting both lncRNAs and PCGs, generating double-strand breaks that produced targeted deletions within the selected loci. We next adapted this design for in vivo AAV8 co-delivery to mouse liver, where we observed low-frequency genomic deletions at the targeted loci, highlighting the need for further optimization of in vivo editing conditions. Collectively, the application of the pgRNA deletion strategy across three distinct delivery platforms —plasmid transfection, lentiviral infection, and AAV8 injection—with variable degrees of success demonstrates the versatility and adaptability of the knockout model for targeting multiple genes within the GH regulatory network and establishes a flexible framework for investigating additional gene networks with potential disease relevance, including pathways linked to NAFLD.","abstract_has_math":false,"creators":["Pierson, Jacob"],"institution":"Boston University","degree_name":"M.A.","degree_level":"masters","degree_discipline":"Molecular Biology, Cell Biology & Biochemistry","degree_department":null,"school":null,"contributors":[],"advisors":["Waxman, David J"],"committee_chairs":[],"committee_members":[],"year":2026,"date_issued":"2026","date_published":"2026","updated_at":"2026-11-18T19:49:51Z","subjects":["Molecular biology","Genetics","Bioengineering","CRISPR-Cas9","Genome editing","Growth-hormone signaling","Non-Alcoholic Fatty Liver Disease (NALFD)","Paired-guide RNA","Sex-biased gene expression"],"languages":["en_US"],"rights":[],"rights_urls":[],"identifier_entries":[],"person_identifier_entries":[]},"links":{"outbound_url":"https://hdl.handle.net/2144/53644","outbound_label":"Handle","outbound_source":"dc:identifier.uri","record_url":"https://hdl.handle.net/2144/53644","record_label":"Repository record","record_kind":"handle","record_source":"dc:identifier.uri","download_url":null,"download_label":null,"download_source":null,"access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://open.bu.edu/oai/request?verb=GetRecord&metadataPrefix=dim&identifier=oai%3Aopen.bu.edu%3A2144%2F53644","prefix":"dim"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.advisor","label":"Advisor","values":["Waxman, David J"]},{"key":"dc:creator","label":"Author","values":["Pierson, Jacob"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.accessioned","label":"Dc Date Accessioned","values":["2026-10-08T18:22:50Z"]},{"key":"dc:date.available","label":"Dc Date Available","values":["2026-10-08T18:22:50Z"]},{"key":"dc:date.issued","label":"Date","values":["2026"]},{"key":"dc:date.updated","label":"Dc Date Updated","values":["2026-10-07T16:15:34Z"]},{"key":"dc:type","label":"Dc Type","values":["Thesis/Dissertation"]},{"key":"thesis:degree_discipline","label":"Discipline","values":["Molecular Biology, Cell Biology & Biochemistry"]},{"key":"thesis:degree_level","label":"Degree Level","values":["masters"]},{"key":"thesis:degree_name","label":"Degree Name","values":["M.A."]},{"key":"thesis:institution_name","label":"Thesis Institution Name","values":["Boston University"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Molecular biology","Genetics","Bioengineering","CRISPR-Cas9","Genome editing","Growth-hormone signaling","Non-Alcoholic Fatty Liver Disease (NALFD)","Paired-guide RNA","Sex-biased gene expression"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language.iso","label":"Language (ISO)","values":["en_US"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["https://hdl.handle.net/2144/53644"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description","label":"Description","values":["2026"]},{"key":"dc:description.abstract","label":"Abstract","values":["In mice, as well as rats and humans, pituitary growth hormone (GH) secretion patterns exhibit distinct sexual dimorphism. This sex differential secretion pattern drives sex-biased expression of numerous long non-coding RNAs (lncRNAs) and protein-coding genes (PCGs). The regulation and functional roles of these genes within the GH gene regulatory network are understudied, but have been associated with liver disease, including non-alcoholic fatty liver disease (NAFLD). To address this gap, we developed a CRISPR-Cas9-mediated paired-guide RNA (pgRNA) deletion strategy as a loss-of-function model to generate targeted genomic deletions within identified sex-biased genes. The original design was established in NIH3T3 cells by co-transfection of pgRNA and CRISPR-Cas9 plasmids targeting deletions in lncRNAs and expanded to a lentiviral co-infection system targeting both lncRNAs and PCGs, generating double-strand breaks that produced targeted deletions within the selected loci. We next adapted this design for in vivo AAV8 co-delivery to mouse liver, where we observed low-frequency genomic deletions at the targeted loci, highlighting the need for further optimization of in vivo editing conditions. Collectively, the application of the pgRNA deletion strategy across three distinct delivery platforms —plasmid transfection, lentiviral infection, and AAV8 injection—with variable degrees of success demonstrates the versatility and adaptability of the knockout model for targeting multiple genes within the GH regulatory network and establishes a flexible framework for investigating additional gene networks with potential disease relevance, including pathways linked to NAFLD."]},{"key":"dc:title","label":"Title","values":["Development of a CRISPR-Cas9 paired-guide RNA deletion strategy for functional studies of sex-biased genes in mouse liver"]}]}],"canonical_facts":{"dc:contributor.advisor":["Waxman, David J"],"dc:creator":["Pierson, Jacob"],"dc:date.accessioned":["2026-10-08T18:22:50Z"],"dc:date.available":["2026-10-08T18:22:50Z"],"dc:date.issued":["2026"],"dc:date.updated":["2026-10-07T16:15:34Z"],"dc:description":["2026"],"dc:description.abstract":["In mice, as well as rats and humans, pituitary growth hormone (GH) secretion patterns exhibit distinct sexual dimorphism. This sex differential secretion pattern drives sex-biased expression of numerous long non-coding RNAs (lncRNAs) and protein-coding genes (PCGs). The regulation and functional roles of these genes within the GH gene regulatory network are understudied, but have been associated with liver disease, including non-alcoholic fatty liver disease (NAFLD). To address this gap, we developed a CRISPR-Cas9-mediated paired-guide RNA (pgRNA) deletion strategy as a loss-of-function model to generate targeted genomic deletions within identified sex-biased genes. The original design was established in NIH3T3 cells by co-transfection of pgRNA and CRISPR-Cas9 plasmids targeting deletions in lncRNAs and expanded to a lentiviral co-infection system targeting both lncRNAs and PCGs, generating double-strand breaks that produced targeted deletions within the selected loci. We next adapted this design for in vivo AAV8 co-delivery to mouse liver, where we observed low-frequency genomic deletions at the targeted loci, highlighting the need for further optimization of in vivo editing conditions. Collectively, the application of the pgRNA deletion strategy across three distinct delivery platforms —plasmid transfection, lentiviral infection, and AAV8 injection—with variable degrees of success demonstrates the versatility and adaptability of the knockout model for targeting multiple genes within the GH regulatory network and establishes a flexible framework for investigating additional gene networks with potential disease relevance, including pathways linked to NAFLD."],"dc:identifier.uri":["https://hdl.handle.net/2144/53644"],"dc:language.iso":["en_US"],"dc:subject":["Molecular biology","Genetics","Bioengineering","CRISPR-Cas9","Genome editing","Growth-hormone signaling","Non-Alcoholic Fatty Liver Disease (NALFD)","Paired-guide RNA","Sex-biased gene expression"],"dc:title":["Development of a CRISPR-Cas9 paired-guide RNA deletion strategy for functional studies of sex-biased genes in mouse liver"],"dc:type":["Thesis/Dissertation"],"thesis:degree_discipline":["Molecular Biology, Cell Biology & Biochemistry"],"thesis:degree_level":["masters"],"thesis:degree_name":["M.A."],"thesis:institution_name":["Boston University"]},"updated_at":"2026-11-18T19:49:51Z"}